We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




1 Hour Direct-From-Blood Test Detects 95% Of Pathogens Associated with Bloodstream Infections

By LabMedica International staff writers
Posted on 11 Dec 2024

Early detection is crucial for treating a variety of infections, particularly sepsis. More...

Sepsis is responsible for one in three hospital deaths in the U.S., and septic shock has a global mortality rate of 30-40%. However, early diagnosis remains difficult due to the non-specific and often subtle symptoms. Currently, the standard method for diagnosing sepsis involves complex blood culture tests, which can take several days to provide results. This method, over 40 years old, is limited to identifying 'viable' organisms, often overlooking a wide array of microbial markers present in the blood. Now, a groundbreaking one-hour test can detect 95% of pathogens linked to bloodstream infections (BSIs) that could lead to sepsis, along with specific genetic markers for antimicrobial resistance (AMR).

deepull’s (Barcelona, Spain) UllCORE BSI Test and UllCore system offer 50 reportable results, identifying pathogens and antibiotic resistance markers directly from blood within about one hour. This real-time multiplex PCR system extracts microbial DNA from 8 mL of whole blood, bypassing the slow blood culture process. The assay covers a broad range of bacterial targets, fungi, and genetic determinants of antibiotic resistance. UllCORE’s rapid results and high sensitivity empower clinicians to make better-informed decisions, minimizing the risks of over- and under-treatment with antibiotics and contributing to efforts to combat antimicrobial resistance in hospitals. While focused on sepsis, deepull envisions its system as useful for diagnosing various other acute infections. The company has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the UllCORE BSI Test.

“We are thrilled to receive breakthrough designation from the FDA,” said Jordi Carrera, Chief Executive Officer and Co-Founder of deepull. “Providing life-saving results for patients suspected of serious infection in one hour represents a significant advantage over current standard of care blood culture. Faster pathogen identification and AMR testing will provide clinicians with a powerful tool to more quickly and accurately tailor antimicrobial therapy, which could lead to faster patient recovery, shorter length of stay, and reduced morbidity and mortality.”

Related Links:
deepull


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.